The estimated Net Worth of Swan Sit is at least $7.43 mil dollars as of 31 January 2024. Ms. Sit owns over 3,318 units of Novabay Pharmaceuticals Inc stock worth over $7,429 and over the last 4 years she sold NBY stock worth over $0. In addition, she makes $0 as Independent Director at Novabay Pharmaceuticals Inc.
Swan has made over 7 trades of the Novabay Pharmaceuticals Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently she exercised 3,318 units of NBY stock worth $1,590 on 31 January 2024.
The largest trade she's ever made was exercising 30,000 units of Novabay Pharmaceuticals Inc stock on 21 May 2022 worth over $14,379. On average, Swan trades about 2,727 units every 64 days since 2020. As of 31 January 2024 she still owns at least 15,499 units of Novabay Pharmaceuticals Inc stock.
You can see the complete history of Ms. Sit stock trades at the bottom of the page.
Swan Sit serves as Independent Director of the Company. She currently acts as an independent business consultant to various public and private companies. Most recently she served as the Vice President of NA Digital Commerce Capabilities, Business Operations and Service and the Vice President of Global Digital Marketing of Nike, Inc. from 2018 to 2019. Ms. Sit’s experience includes digital transformation experience supplemented by management consulting, brand management and advertising. She has built front-end consumer experiences across ecommerce, omnichannel, mobile, media, social, apps and innovation as well as integrated back-end operations. Ms. Sit previously was the Vice President of Global Digital of Revlon and Elizabeth Arden, Inc. from 2015 to 2017 and the Executive Director of Strategy and Planning, Online of The Estée Lauder Companies, Inc. Ms. Sit received an MBA from Columbia Business School and a B.A. in Economics from Harvard University.
Swan Sit is 43, she's been the Independent Director of Novabay Pharmaceuticals Inc since 2019. There are 6 older and 2 younger executives at Novabay Pharmaceuticals Inc. The oldest executive at Novabay Pharmaceuticals Inc is Paul Freiman, 81, who is the Independent Director.
Swan's mailing address filed with the SEC is C/O NOVABAY PHARMACEUTICALS, INC., 2000 POWELL STREET, SUITE 1150, EMERYVILLE, CA, 94608.
Over the last 18 years, insiders at Novabay Pharmaceuticals Inc have traded over $3,799,939 worth of Novabay Pharmaceuticals Inc stock and bought 24,568,662 units worth $26,237,091 . The most active insiders traders include Pharma (Singapore) Pte. Ltd..., Pioneer Pharma Holdings Ltd..., ePharma (Hong Kong) Co Ltd P.... On average, Novabay Pharmaceuticals Inc executives and independent directors trade stock every 57 days with the average trade being worth of $127,779. The most recent stock trade was executed by Paul E. Freiman on 11 May 2023, trading 858 units of NBY stock currently worth $411.
novabay pharmaceuticals $nby is a biopharmaceutical company focusing, commercializing and developing its non-antibiotic anti-infective products to address the unmet therapeutic needs of the global eye care market. novabay has two distinct product categories: the neutrox™ family of products, led by avenova™ for the eye care market, neutrophase® for wound care, and cellerx™ for the dermatology market; and aganocide® compounds, led by auriclosene™. novabay is commercializing avenova, a prescription lid and lash hygiene product for the management of the chronic eye conditions of blepharitis and meibomian gland dysfunction – also known as dry eye syndrome. these difficult-to-manage conditions affect approximately 30 million americans, with an annual market potential that novabay estimates at $500 million. novabay is gaining market traction with avenova through its 35-medical direct sales representatives under veteran leadership. avenova is available for order in 90% of all pharmacies across
Novabay Pharmaceuticals Inc executives and other stock owners filed with the SEC include: